H.C. Wainwright lowered the firm’s price target on Allogene Therapeutics to $12 from $23 and keeps a Buy rating on the shares post the Q3 report. The analyst removed follicular lymphoma from the firm’s forecasts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics (NASDAQ:ALLO) Blasts Up on Earnings, New Data
- Allogene Therapeutics presents preclinical data on allogeneic CAR T candidate
- Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
- Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
- Allogene Therapeutics presents preclinical data on Cloak, Dagger tech